The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest…The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest blood-marker groups.
At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.